Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Prostatic Neoplasms 2Tongue Neoplasms 1Thymoma 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma, Endometrial Stromal 1Sarcoma 1Rhabdomyosarcoma 1Rectal Neoplasms 1Pleural Effusion, Malignant 1Pancreatic Neoplasms 1Melanoma 1Liposarcoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Fibrosarcoma 1Esophageal Neoplasms 1Dermatofibrosarcoma 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

aldesleukin 65Cyclophosphamide 45fludarabine phosphate 30fludarabine 27Interleukin-2 24incomplete Freund's adjuvant 22Ipilimumab 17Specimen Handling 14MART-1 Antigen 14CTLA-4 Antigen 14sargramostim 13Magnetic Resonance Spectroscopy 13Biopsy 13montanide ISA 51 11Nivolumab 11Filgrastim 11Sorafenib 10Interferon-alpha 9trametinib 8pembrolizumab 8dabrafenib 8Sirolimus 7Bevacizumab 7temsirolimus 6Temozolomide 6Taxes 5Paclitaxel 5Introns 5Gene Expression Profiling 5Carboplatin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Melanoma × saracatinib × Clear all
NCT00669019 2014-05-21

Saracatinib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery

National Cancer Institute (NCI)

Phase 2 Completed
23 enrolled 6 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡